696582-88-4

Usage

Uses

Used in Pharmaceutical Industry:
(R)-3-(Methoxymethyl)morpholine HCl is used as a building block for the synthesis of various drugs due to its unique structure and chirality. It can be incorporated into the molecular design of pharmaceutical compounds, potentially enhancing their efficacy and selectivity.
Used in Material Science:
(R)-3-(Methoxymethyl)morpholine HCl is used in the development of new materials and fine chemicals. Its unique structure and properties can contribute to the creation of innovative materials with specific characteristics, such as improved solubility, stability, or reactivity.
Used in Chemical Synthesis:
(R)-3-(Methoxymethyl)morpholine HCl is used as a reagent or intermediate in the synthesis of various organic compounds. Its versatility and functional groups make it a valuable component in the preparation of complex molecules and pharmaceutical intermediates.
Used in Solubility and Stability Enhancement:
The chloride salt form of (R)-3-(Methoxymethyl)morpholine HCl can provide improved solubility and stability in certain applications. This can be particularly useful in the formulation of pharmaceutical compounds, where solubility and stability are critical factors for drug delivery and efficacy.

InChI:InChI=1/C6H13NO2/c1-8-4-6-5-9-3-2-7-6/h6-7H,2-5H2,1H3/t6-/m1/s1

Upstream product

• 917572-28-2 (S)-4-benzyl-3-(chloromethyl)morpholine 
• 101376-26-5 (3R)-4-benzyl-3-(hydroxymethyl)-morpholine 
• 1445591-33-2 (R)-benzyl 3-(methoxymethyl)morpholine-4-carboxylate 
• 211053-49-5 (R)-3-hydroxymethylmorpholine 
• 441717-93-7 (R)-benzyl 3-(hydroxymethyl)morpholine-4-carboxylate 

Relevant academic research and scientific papers

Development of the First Generation of Disulfide-Based Subtype-Selective and Potent Covalent Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors

Pyruvate dehydrogenase kinases (PDKs) are overexpressed in most cancer cells and are responsible for aberrant glucose metabolism. We previously described bis(4-morpholinyl thiocarbonyl)-disulfide (JX06, 16) as the first covalent inhibitor of PDK1. Here, on the basis of the scaffold of 16, we identify two novel types of disulfide-based PDK1 inhibitors. The most potent analogue, 3a, effectively inhibits PDK1 both at the molecular (kinact/Ki = 4.17 × 103 M-1 s-1) and the cellular level (down to 0.1 μM). In contrast to 16, 3a is a potent and subtype-selective inhibitor of PDK1 with >40-fold selectivity for PDK2-4. 3a also significantly alters glucose metabolic pathways in A549 cells by decreasing ECAR and increasing ROS. Moreover, in the xenograft models, 3a shows significant antitumor activity with no negative effect to the mice weight. Collectively, these data demonstrate that 3a may be an excellent lead compound for the treatment of cancer as a first-generation subtype-selective and covalent PDK1 inhibitor.

NOVEL HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formula (I): wherein Rings A and A' are independently 5-membered optionally substituted aromatic heterocycles; Q is C(=O)NR1R1' or formula U is C(R4)2, O, S, S(=O)2, C(R4)2C(R4)2, CH2O, OCH2, CH2S, SCH2, CH2S(=O)2, S(=O)CH2 or C=C(Ru )2; X is CH2, CHR12, CR12R12, O, S, S(=O)2 or NRx; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.